Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device maker Atrion (ATRI 1.27%) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Atrion and see what CAPS investors are saying about the stock right now.

Atrion facts

Headquarters (founded)

Allen, Texas (1944)

Market Cap

$395.8 million

Industry

Health care supplies

Trailing-12-Month Revenue

$116.1 million

Management

CEO David Battat (since 2011)
CFO Jeffery Strickland (since 1997)

Return on Equity (average, past 3 years)

18.1%

Cash / Debt

$38.7 million / $0

Dividend Yield

1.1%

Competitors

Baxter International (BAX -0.55%)Covidien (COV.DL)Teleflex (TFX 0.48%)

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 257 members who have rated Atrion believe the stock will outperform the S&P 500 going forward.

Just last month, one of those bulls, fellow Fool Buck Hartzell (TMFBuck), succinctly summed up the outperform case for our community: "Great capital allocators here. Look at their returns on equity. Surprisingly diversified for a small cap company. I like the ownership and the capital allocation decisions. This is a long term hold."

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Atrion may not be your top choice.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.